Clinical trials
Chronic Hepatitis clinical trials
Below are recruiting chronic hepatitis clinical trials, each written for real people, not researchers. We’re tracking 134 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06051045Recruiting
Bulevirtide for chronic hepatitis B and D
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
StockholmAges 18 years+ - NCT06295328RecruitingPhase 1/Phase 2
Terbinafine for chronic hepatitis B: safety and effect
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
Amsterdam, North HollandAges 18–60 - NCT06525909Recruiting
Immune status in chronic hepatitis B
This study looks at how the immune system changes over time in people with chronic hepatitis B. It will help doctors better understand the stages of the disease to guide treatment decisions.
Wuhan, HubeiAges 18–50 - NCT06885710RecruitingPhase 1
T cell therapy with antivirals for chronic hepatitis B
This study tests a new treatment that uses your own immune cells (T cells) modified to attack the hepatitis B virus, combined with standard antiviral medication. It is for people with chronic hepatitis B who have a specific HLA type and no advanced liver scarring.
ShanghaiAges 18–65 - NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+ - NCT04139850Recruiting
Study of adults with chronic hepatitis B in Korea
This study follows adults with long-term hepatitis B to better understand their health over time and improve care. If you have chronic hepatitis B and can do regular check-ins, you may be invited to join.
SeoulAges 19 years+ - NCT07487623Recruiting
Nutritional supplement for liver protection in hepatitis C
This trial tests whether a special nutritional supplement can protect the liver in people with chronic hepatitis C. If you have mild to moderate liver damage and meet the criteria, you may be able to join.
Guadalajara, JaliscoAges 18–69 - NCT07328711RecruitingEarly Phase 1
Immunotherapy for chronic hepatitis B after HBsAg loss
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
Beijing, Beijing MunicipalityAges 18–60 - NCT07630727RecruitingPhase 2
AHB-171 treatment for chronic hepatitis B
This study tests whether a new drug called AHB-171 can help treat chronic hepatitis B (a long-term liver infection). You would receive the drug by injection under your skin and be monitored to see if it helps reduce the hepatitis B virus and improves liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07511218RecruitingPhase 1
Study of AHB-171 for stable chronic hepatitis B
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Ch’ang-ch’un, JilinAges 18–65 - NCT05182463RecruitingPhase 4
Peginterferon test for inactive chronic hepatitis B
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
Guangzhou, GuangdongAges 18–60 - NCT07573943RecruitingPhase 4
ASC22 with peginterferon to cure chronic hepatitis B
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07051187RecruitingPhase 1
WGc0201 for chronic hepatitis B
This trial tests a new drug called WGc0201 in adults with chronic hepatitis B who have controlled their virus with standard antiviral pills. It aims to see if WGc0201 can further reduce hepatitis B surface antigen (HBsAg) levels.
Chengdu, SichuanAges 18–65 - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT07200908RecruitingPhase 3
Comparing brelovitug and bulevirtide for hepatitis delta
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
GrazAges 18–99 - NCT06216470RecruitingPhase 2
Testing an antibody treatment for chronic hepatitis B
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
Toronto, OntarioAges 18–65 - NCT06650852RecruitingPhase 2
A study of 3 drugs for chronic hepatitis B
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
Beijing, Beijing MunicipalityAges 18–60 - NCT05181826Recruiting
Blood collection study for cancer and benign diseases
This study collects blood samples from people with different health conditions (cancer, diabetes, liver disease, etc.) and from healthy volunteers. The goal is to find markers in the blood that could help detect or monitor diseases.
Redondo Beach, CaliforniaAges 18 years+ - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06696664Recruiting
Genetic study of chronic hepatitis B cure with long-acting interferon
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
Beijing, Beijing MunicipalityAges 18–70 - NCT07079150Recruiting
Long-term pegylated interferon study for HBV families with poor outcomes
This study looks at how well pegylated interferon alpha-2b works over the long term for people with chronic hepatitis B who come from families where the virus has caused serious liver problems like cirrhosis or liver cancer. The goal is to see if this treatment can help prevent these bad outcomes in family members.
Xi'an, ShaanxiAges 18–70 - NCT07491848Recruiting
Mouth health study for hepatitis B and D patients
This study looks at mouth health in people with hepatitis B and D, including those taking a medicine called bulevirtide and those not taking it. It may help understand how these infections affect the mouth and gums.
CraiovaAges 18 years+ - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07146100Recruiting
Long-term follow-up after AHB-137 treatment for hepatitis B
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
Hefei, AnhuiAges 18 years+
Hear when a new Chronic Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis?
- Yes. Clin2 currently lists 134 recruiting chronic hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.